Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. - Test2 - elhamkhani - TriplyDB

Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.

Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.

http://www.wikidata.org/entity/Q31138173

about

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.DNA Immunization for HIV Vaccine Development.Evaluation of the safety and adjuvant effect of a detoxified listeriolysin O mutant on the humoral response to dengue virus antigens.

P2860

Q34057711-B13DFDFD-0078-413A-88DD-DCF455F9E01C Q35757125-4CAB821C-CC72-400A-86C2-DD613888EE35 Q36466129-900492ED-6E2C-463C-A88E-7CBE4C60DD28 Q36977750-09E16390-8929-4B33-923B-95EA211DAAAD Q37692880-9A9954E4-E0CB-4991-8AC5-5B1D70E4061E Q38243948-DE057DDD-F1FD-4461-9A6B-2673F0F6ACDD Q38581981-C0E72740-21DE-40E5-921B-D5D448F1504E Q40078764-421FB669-06EF-4FB7-9EA4-FACA3742C991

P2860

Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.

http://www.wikidata.org/entity/Q31138173

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Serum cytokine profiles associ ...... in boost vaccination strategy.

@ast

Serum cytokine profiles associ ...... in boost vaccination strategy.

@en

type

label

Serum cytokine profiles associ ...... in boost vaccination strategy.

@ast

Serum cytokine profiles associ ...... in boost vaccination strategy.

@en

prefLabel

Serum cytokine profiles associ ...... in boost vaccination strategy.

@ast

Serum cytokine profiles associ ...... in boost vaccination strategy.

@en

P1433

Q31138173-858D287C-4BFE-4C07-8BBD-08001C64CF0B

P1476

Q31138173-B93C5C92-29AF-4165-AE4E-A475980E49B7

P2093

Q31138173-5A93C1AB-5EB3-4131-99AA-DD903D3BD4C4

Q31138173-6EF295CD-973C-4D07-B7A8-FD6B821AE45D

Q31138173-79EE54ED-E666-4497-B35A-3AB73D7BE908

Q31138173-80219D9C-3805-42DF-A27C-5A67BABBB9A1

Q31138173-8B3EC73C-2113-46ED-A5BB-574EF3F86961

Q31138173-A18551E4-E876-43C2-B012-EA02B3064506

P2860

Q31138173-031A82CF-F165-4C7F-B8EB-8D70F56F9444

Q31138173-0671CB5B-451E-450C-8900-C30C42A08B6C

Q31138173-07C232C3-B747-4088-9EFF-49A7218A529E

Q31138173-0B9A1CE3-A039-467D-9BA0-9705C0CEE6EA

Q31138173-16342DC4-03E0-4069-8BCE-BD92C9897EEF

Q31138173-2555F089-52C9-44B2-9D7E-BF3FCCBAA7D4

Q31138173-2DCF2565-481F-4545-991D-452004A0A76B

Q31138173-2E35FBE2-18D7-4868-BDF7-A0E77CAD861E

Q31138173-363AFCFE-5DC9-4993-8CAF-A9CDAF600C1B

Q31138173-394FA46C-5ADF-4D95-B1A6-D7B907F9A9EE

P304

Q31138173-A3FE6110-A855-457A-9143-D747921216F0

P31

Q31138173-29AE25A5-7F3F-4A6A-B476-1224726272AB

P356

Q31138173-E25B9619-E2D3-4374-8B21-E8CCEC8766CB

P407

Q31138173-E619D676-2F5D-425E-80B0-B3425C3DA91C

P433

Q31138173-4AAA6157-C7EA-4A0D-9169-9423826D4E60

P478

Q31138173-3191C27A-A37A-4F2A-B5C1-8CF12BC68669

P50

Q31138173-11DE34D2-5AD6-436F-AE0E-FD8DF45F8E1F

P577

Q31138173-299F9894-DF6C-4E3B-89CE-DF15B86DAF99

P5875

Q31138173-8BE399C2-0494-48A5-9ADE-A91294149739

P698

Q31138173-E478A12C-EC50-425F-8A7C-F32AF07EB70B

P932

Q31138173-682A00CA-E3AE-466B-91DE-F35AEA357F83

P356

JOURNAL.PONE.0074820

P1433

P1476

Serum cytokine profiles associ ...... in boost vaccination strategy.

@en

P2093

Kim West

http://www.w3.org/2001/XMLSchema#string

Kimberly Pouliot

http://www.w3.org/2001/XMLSchema#string

Rachel Buglione-Corbett

http://www.w3.org/2001/XMLSchema#string

Robyn Marty-Roix

http://www.w3.org/2001/XMLSchema#string

Shan Lu

http://www.w3.org/2001/XMLSchema#string

Shixia Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

The neutrophil as a cellular source of chemokines.

Immune responses to ISCOM formulations in animal and primate models.

Directing transition from innate to acquired immunity: defining a role for IL-6.

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Towards an understanding of the adjuvant action of aluminium.

P304

e74820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0074820

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256477684

http://www.w3.org/2001/XMLSchema#string

P698

24019983

http://www.w3.org/2001/XMLSchema#string

P932

3760864

http://www.w3.org/2001/XMLSchema#string